|
| Index | - | P/E | - | EPS (ttm) | -0.43 | Insider Own | 2.10% | Shs Outstand | 16.73M | Perf Week | -19.75% |
| Market Cap | 382.51M | Forward P/E | - | EPS next Y | -0.26 | Insider Trans | 0.00% | Shs Float | 12.52M | Perf Month | -14.24% |
| Income | -6.80M | PEG | - | EPS next Q | -0.14 | Inst Own | 10.90% | Short Float | 2.59% | Perf Quarter | -1.54% |
| Sales | 12.80M | P/S | 29.88 | EPS this Y | -1.60% | Inst Trans | 100.35% | Short Ratio | 0.66 | Perf Half Y | 141.99% |
| Book/sh | 0.14 | P/B | 123.07 | EPS next Y | 50.00% | ROA | -27.70% | Target Price | - | Perf Year | 390.88% |
| Cash/sh | 0.91 | P/C | 19.03 | EPS next 5Y | 30.00% | ROE | -409.40% | 52W Range | 2.90 - 31.29 | Perf YTD | 8.43% |
| Dividend | - | P/FCF | - | EPS past 5Y | 37.50% | ROI | -26.20% | 52W High | -44.33% | Beta | 1.00 |
| Dividend % | - | Quick Ratio | 6.90 | Sales past 5Y | 22.80% | Gross Margin | 71.10% | 52W Low | 501.25% | ATR | 1.84 |
| Employees | 67 | Current Ratio | 8.00 | Sales Q/Q | 15.60% | Oper. Margin | -48.70% | RSI (14) | 37.37 | Volatility | 10.05% 9.72% |
| Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | 12.70% | Profit Margin | -52.90% | Rel Volume | 0.81 | Prev Close | 17.23 |
| Shortable | Yes | LT Debt/Eq | 8.88 | Earnings | Mar 04 AMC | Payout | - | Avg Volume | 494.12K | Price | 17.42 |
| Recom | 2.00 | SMA20 | -15.65% | SMA50 | -20.99% | SMA200 | 44.67% | Volume | 395,808 | Change | 1.10% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite